JPMorgan plans four-year review notes on S&P 500, SPDR S&P Biotech

By Susanna Moon

Chicago, Oct. 19 – JPMorgan Chase Financial Co. LLC plans to price 0% review notes due Oct. 26, 2020 linked to the lesser performing of the S&P 500 index and the SPDR S&P Biotech exchange-traded fund, according to a 424B2 filing with the Securities and Exchange Commission.

The notes are guaranteed by JPMorgan Chase & Co.

The notes will be called at par plus an annual call premium of at least 16.5% if each component closes at or above its initial level on any annual review date.

The payout at maturity will be par unless any component finishes below its 50% trigger level, in which case the payout will be par plus the return of the worse performing component, with full exposure to any losses.

J.P. Morgan Securities LLC is the agent.

The notes will price on Oct. 21 and settle on Oct. 28.

The Cusip number is 46646E2D3.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.